Trials / Unknown
UnknownNCT03327285
C-CAR011 Treatment in Subjects With ALL After HSCT
A Study Evaluating Safety and Efficacy of CBM.CD19-targeted Chimeric Antigen Receptor T Cells (C-CAR011) Treatment in Subjects With Acute Lymphoblastic Leukemia(ALL) After Hematopoietic Stem Cell Transplantation（HSCT）
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 15 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-center, prospective clinical study evaluating safety and efficacy of C-CAR011 treatment in subjects with ALL after HSCT
Detailed description
A study evaluating safety and efficacy of CBM.CD19-targeted chimeric antigen receptor T cells (C-CAR011) treatment in subjects with acute lymphoblastic leukemia(ALL) after hematopoietic stem cell transplantation（HSCT）. The amount of cells received：1.0-5.0×10\^6CAR+T cells/kg
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | C-CAR011 | CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011) |
Timeline
- Start date
- 2018-03-01
- Primary completion
- 2021-02-28
- Completion
- 2021-04-30
- First posted
- 2017-10-31
- Last updated
- 2020-10-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03327285. Inclusion in this directory is not an endorsement.